Lola.com

lola.com

Lola.com makes Agile Travel Management real by providing a super simple way to manage, book and report on business travel, saving employers and travelers time and money. Happy employee travel experiences within a policy can be set up in five minutes. Lola.com uses machine learning and 24/7 support to help travelers easily book trips, while empowering managers to create policies, view budgets and expenditures, and monitor their globetrotting team efficiently. Based in Boston, the company was founded in 2015 by Paul English, co-founder of the travel booking site KAYAK, and is led by CEO Mike Volpe, previously CMO at HubSpot.

C-Suite On Deck

Jeanne Hopkins, CMO at Lola.com has profound expertise in data-driven, high-velocity customer acquisition and marketing organizations and inbound-based lead gen programs to support global demand for high-growth SaaS companies.

Jeanne is also the co-author of "Go Mobi...

Events

Related News

BUSINESS INSIGHTS

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

news image

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

BioPharma Dive | January 28, 2020

news image

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More

PHARMACY MARKET

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

news image

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More

BUSINESS INSIGHTS

CATALENT ANNOUNCES NEW OPERATING STRUCTURE

Catalent, Inc | July 06, 2022

news image

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue. According to Alessandro Mas...

Read More
news image

BUSINESS INSIGHTS

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More
news image

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

BioPharma Dive | January 28, 2020

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More
news image

PHARMACY MARKET

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More
news image

BUSINESS INSIGHTS

CATALENT ANNOUNCES NEW OPERATING STRUCTURE

Catalent, Inc | July 06, 2022

Catalent, Inc. the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue. According to Alessandro Mas...

Read More